Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Oncology Institute
TOI
Oncology Institute
Fourth Quarter 2024 Financial Highlights
WA
WaneInvestmentHouse
Not Invested
Community Contributor
Published
08 Apr 25
Updated
08 Apr 25
5
Set Fair Value
0
votes
Share
WaneInvestmentHouse
's Fair Value
US$1.37
200.0% overvalued
intrinsic discount
08 Apr
US$4.11
Loading
1Y
647.3%
7D
3.8%
Author's Valuation
US$1.4
200.0% overvalued
intrinsic discount
WaneInvestmentHouse's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
WaneInvestmentHouse
's
Fair Value
US$1.4
200.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-60m
393m
2018
2020
2022
2024
2025
2026
2028
Revenue US$393.4m
Earnings US$7.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
16.34%
Healthcare Services revenue growth rate
0.29%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$7.08m
Earnings '28
x
19.05x
PE Ratio '28
=
US$134.93m
Market Cap '28
US$134.93m
Market Cap '28
/
79.84m
No. shares '28
=
US$1.69
Share Price '28
US$1.69
Share Price '28
Discounted to 2025 @ 7.37% p.a.
=
US$1.37
Fair Value '25
